NCT07525258NARecruitingAccepts Healthy Volunteers

Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)

Yale University

Start Date

4/5/2026

Completion Date

4/1/2029

Summary

The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system. Exclusion Criteria: * Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.

Interventions

BEHAVIORAL

Implementation Intervention

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Alcohol Use DisorderAlcohol-associated Liver Disease

Locations

Yale School of Medicine/Yale-New Haven Health

New Haven, Connecticut 06520

United States